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Elimination of HIV-1 requires clearance and removal of integrated proviral DNA from infected
cells and tissues. Here, sequential long-acting slow-effective release antiviral therapy (LASER
ART) and CRISPR-Cas9 demonstrate viral clearance in latent infectious reservoirs in HIV-1
infected humanized mice. HIV-1 subgenomic DNA fragments, spanning the long terminal
repeats and the Gag gene, are excised in vivo, resulting in elimination of integrated proviral
DNA; virus is not detected in blood, lymphoid tissue, bone marrow and brain by nested and
digital-droplet PCR as well as RNAscope tests. No CRISPR-Cas9 mediated off-target effects
are detected. Adoptive transfer of human immunocytes from dual treated, virus-free animals
to uninfected humanized mice fails to produce infectious progeny virus. In contrast, HIV-1 is
readily detected following sole LASER ART or CRISPR-Cas9 treatment. These data provide
proof-of-concept that permanent viral elimination is possible.
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According to UNAIDS, it is estimated that more than 36.7million people worldwide are infected with the humanimmunodeficiency virus type one (HIV-1) and >5000
individuals worldwide are newly infected each day. In the clinic,
antiretroviral therapy (ART) restricts viral infection by stalling
various steps of the viral life cycle. However, ART fails to elim-
inate integrated copies of HIV-1 proviral DNA from the host
genome1,2. As such, virus persists in a latent state within infec-
tious reservoirs; and ART cessation readily leads to viral reacti-
vation and disease progression to acquired immunodeficiency
syndrome (AIDS)3. Thus, a major issue for any HIV-1 curative
strategy is the means to eliminate either integrated proviral DNA
or the cells that harbor virus without collateral cytotoxic reac-
tions. However, elimination of HIV-1 infection in its infected
human host is documented only in two individuals4,5. There are
several reasons why success has not yet been realized. This
includes inadequate therapeutic access to viral reservoirs,
rapid spread of infection by continuous sources of virus and
susceptible cells and a failure to eliminate residual latent inte-
grated proviral DNA. All single or combination therapeutic
approaches preclude HIV-1 cure as viral rebound universally
follows ART cessation6–10. Yet, another obstacle towards elim-
ination of infection is that viral latency is established after
infection onset and precedes peak viremia. This underscores that
early intervention with potent antiretroviral medicines may help
to further reduce the size of the reservoir and ultimately facilitate
viral elimination11. Therefore, multimodal robust pharmaceutic
strategies are needed for complete elimination of HIV-1 if no
viral resurgence after cessation of ART is to be achieved. To
address this need and design a suitable therapeutic strategy, our
laboratories produce highly hydrophobic lipophilic viral reservoir
penetrating antiretroviral prodrugs coined as long-acting slow-
effective release ART (LASER ART). LASER ART properties are
defined by slow drug dissolution, enhanced lipophilicity,
improved bioavailability and limited off-target toxicities,
which directly affect the frequency of ART administration from
daily to weeks. These reduce disease co-morbidity in small ani-
mals and maintains effective antiretroviral drug concentrations in
blood and tissue viral reservoirs from days to weeks12–16. Mac-
rophages enable uptake of significant amounts of intracellular
antiretroviral drug crystals and tightly control ongoing viral
replication by the cells’ slow drug release and transfer to adjacent
CD4+ T cells during cell-to-cell contact or through direct drug
uptake13,14,16–18. However, LASER ART alone cannot rid the
infected host of latent HIV-1 no matter how successful the drugs
may prove to be at restricting viral infection. Thus, in parallel, we
develop CRISPR-Cas9 based gene editing technology using AAV9
delivery that specifically and efficiently excises fragments of
integrated HIV-1 proviral DNA from the host genome19–24. We
realize that CRISPR-Cas9-based technologies could be most
effective in the setting of maximal viral restriction and substantive
reductions in the absolute proviral DNA load. Thus, the two
approaches are combined to examine whether LASER ART and
CRISPR-Cas9 treatments could provide combinatorial benefit for
viral elimination. Here we demonstrate elimination of replication
competent HIV-1 in an experimental model of human infectious
disease. Viral clearance is achieved from HIV-1 infected spleen
and lymphoid tissues as well as a broad range of solid organs
from documented prior infected humanized mice treated with
LASER ART and AAV9-CRISPR-Cas9. This is confirmed in those
mice using ultrasensitive HIV-1 nucleic acid detection methods
by the absence of post-treatment viral rebound; and by the
inability to transfer virus from those infected and dual-treated
mice to replicate uninfected untreated mice. We conclude that
viral elimination by a combination of LASER ART and gene
editing strategy is possible.
Results
Creation and characterization of HIV-1 infected humanized
mice. With the knowledge that few small animal models of HIV-1
reflect actual viral reservoirs and long-term infections, another
system for study is required. This is based both on known species
restrictions for HIV-1 infection and long-term establishment of
tissue reservoirs of infection. Human hematopoietic stem cells
(HSC) reconstituted NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG)
mice produce human T cells, that are broadly susceptible to HIV-
1 infection23–30. The model permits evaluation of long-term viral
infection in blood and tissues and ART-induced HIV-1 latency.
To affirm the model’s relevance for studies of HIV-1 elimination,
we undertook a detailed evaluation of each of the human cell-
virus model components (Fig. 1). First, after irradiation of mice at
birth, animals were engrafted with human CD34+HSC isolated
from cord blood by a single intrahepatic injection. The presence
of human immunocytes in blood was confirmed by flow cyto-
metry. Second, four months after humanization was confirmed
animals were infected with HIV-1ADA at 104 tissue culture
infection dose50 (TCID50)/animal and analyzed for acute
(14 days) (Fig. 1a–d) and chronic (16 weeks infection) (Fig. 1e–g)
paradigm. At sacrifice, human cell reconstitution was confirmed
in tissues (spleen, lymph node, liver, lung and brain) by immu-
nohistochemical staining with human HLA-DR antibodies.
Anatomical localizations and lymphocyte prominence were
confirmed by human cell penetration into the white and red pulp
and germinal centers of spleen. Lymph nodes were enriched with
human cells with anatomical distinctions in the cortex, medulla
and germinal centers. Third, productive HIV-1 infection was
confirmed by HIV-1p24 staining as shown by large numbers of
stained cells. Infection was highest in lymphoid compartments as
compared to liver, lung and brain. A significant CD4+ T-cell
decline and increased CD8+ T-cell numbers were observed as a
consequence of sustained HIV-1 infection. The percentage of
human CD4+ T cells in mice was determined in blood by flow
cytometry at 2, 6, 11, and 15 weeks and showed decline after
infection (Fig. 1f). Plasma viral RNA copies/ml 16 weeks after
HIV-1 infection were readily observed (Fig. 1g).
Generation and pharmacokinetic (PK) testing of LASER ART.
We posit that use of CRISPR-Cas9 strategies developed for the
elimination of HIV-1 proviral DNA are aided by optimal control
of viral replication leading to sustained viral latency (supple-
mentary fig. 1). To this end amongst others, our laboratories have
developed LASER ART that facilitates sustained inhibition of
viral replication by long-acting hydrophobic lipophilic anti-
retroviral nanoparticles11–15. To accomplish this goal, fatty-acid-
modified prodrugs were synthesized as prodrugs for dolutegravir
(DTG), lamivudine (3TC) and abacavir (ABC) by esterification
with myristic acid. The chemical structures and physicochemical
properties were characterized by nuclear magnetic resonance
spectroscopy and Fourier-transform infrared spectroscopy, elec-
trospray ionization mass spectrometry and powder X-ray dif-
fraction11–15. The LASER ART particles were characterized fully
for stability, size, and shape. This included human monocyte-
derived macrophage (MDM) nanoparticle drug uptake, release
and potency. Data sets were obtained for nanoformulated myr-
istoylated NM (NMDTG), NM3TC and NMABC prodrugs and
nanoformulated rilpivirine (NRPV) (Table 1) before being used
in the animal studies. These included individual antiretroviral
activity for each of the nanoformulations. Moreover, complete
PK profiles were performed for each of the nanoformulated drugs
after a single drug nanoformulation injection. These are illu-
strated with the accompanying dosages administered in BALB/c
mice (Table 1). The PK measurements including terminal rate
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constant (λz) and half-life (t1/2), area under the concentration-
time curve (AUC), apparent volume of distribution (Vb/F), total
plasma clearance of drug (CL/F), mean resident time (of the
unchanged drug in the systemic circulation) (MRT), were out-
lined in prior works25–28,12–14,29. These data sets showed tight
control over viral replication, and the short tail of drug removal
from blood and tissue affirmed that any lack of viral rebound
would accurately reflect residual HIV-1 growth rather than any
residual antiretroviral drug present as part of the long-acting
regimen.
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Editing of viral DNA in ART treated T-cells by CRISPR-Cas9.
In earlier studies, we demonstrated editing of HIV-1 proviral
DNA by CRISPR-Cas9 in in vitro and ex vivo T cells18,22. Here,
we adapted a procedure as schematized in supplementary fig 1
and found that at sub-optimum conditions for CRISPR editing of
viral DNA, suppression of viral replication by treatment of cells
with ART enhances the efficiency of proviral DNA editing by
CRISPR. A higher inhibitory effect from LASER-ART compared
to those seen in cells treated with conventional ART on HIV-1
expression was observed (Supplementary Fig. 1b and c).
Accordingly, cleavage of proviral DNA by (lentiviral), CRISPR-
Cas9 was more robust in cells treated with LASER ART than
those treated with conventional ART (supplementary fig. 1d and
e). The integrity of the editing at the designated sites within the
LTR sequences and the specificity of the cleavage were verified by
DNA sequences (supplementary fig. 1f). These observations
suggest that LASER ART therapy, by keeping the integrated HIV-
1 copies to a minimum, improves the ability of CRISPR-Cas9 to
edit integrated proviral DNA.
Viral rebound after LASER ART and AAV9-CRISPR-Cas9
treatment of infected humanized mice. With the model and
therapies in hand, we next evaluated the ability of LASER ART
and CRISPR-Cas9 to affect viral rebound after therapeutic
interruption in HIV-1 infected humanized mice (Fig. 2a). In
these experiments, HSC reconstituted NSG mice (n= 33) were
infected with 104 TCID50 of HIV-1NL4-3 for 2 weeks. Four
representative animals were sacrificed at this time point to
confirm viral infection establishment from various tissues. At this
time, depletion of CD4+ T cells (Fig. 2b) was coincident with
plasma viral RNA at a median of 2.2 × 105 copies/ml (Fig. 2c).
The remaining 29 HIV-1 infected animals were divided into four
groups with four more uninfected untreated animals serving as
uninfected controls. The first group (n= 6) of mice were left
untreated (HIV-1 control), the second group (n= 6) received a
single intravenous (IV) injection of AAV9-CRISPR-Cas9, 1012
GC (genome copy) units, with a volume of 50 μl; the third group
(n= 10) were administered LASER ART that consisted of 45 mg/
kg parent drug equivalents of nanoformulated RPV and myr-
istoylated DTG, and 40 mg/kg parent drug equivalents of myr-
istoylated 3TC and ABC nanoparticles by intramuscular (IM)
injection. A fourth group (n= 7) received LASER ART followed
by AAV9-CRISPR-Cas9. Eight weeks following the last adminis-
tration of LASER ART and five weeks after the single AAV9-
CRISPR-Cas9 treatment animals were observed for evidence of
viral rebound (Fig. 2c). In the group that received LASER ART
with subsequent AAV9-CRISPR-Cas9, viral rebound was not
observed in two animals. Examination of the plasma viral load
(Fig. 2d) for each individual animal showed drastic decline in the
viral copy number to below detectable levels in the group of
animals treated with LASER ART. Removal of LASER ART led to
rebound in all 10 animals treated with LASER ART alone and in
five out of seven animals that received both LASER ART and
AAV9-CRISPR-Cas9. Repeated search for the viral RNA in the
plasma of two animals, M4346 and M4349 (Fig. 2d framed in
red), failed to detect evidence of viral presence. In the absence of
LASER ART, numbers of CD4+ T cells relative to controls were
Fig. 1 Viral and human immune profiles in a HIV-1 infected humanized mice. a Human CD4+ T cells were determined by flow cytometry in blood of
humanized mice before infection (time 0) and on days 3, 5, 7, and 14 after HIV-1ADA infection (n= 4, red color). Each infected animal received 104 TCID50
of titered virus. Uninfected (control, n= 3) animals are shown in blue. b Viral load measurements in plasma of HIV-1 infected humanized mice at 14 days.
c HIV-1 DNA was detected by semi-nested real-time qPCR in tissue of infected animals at 14 days after viral infection (n= 4). d Representative images of
human HLA-DR expression in spleen, lung, and lymph nodes, confirms human cell reconstitution in all animals. Replicate sections were stained for HIV-
1p24 and show large numbers of infected cells. Scale- bars (10 and 40 μm) e–g Immune cell profiles and viral load of tissue were evaluated 16 weeks after
viral infection. e Photomicroscopic images illustrate human cells present in spleens, lymph nodes, lungs, livers and brains of humanized mice. Tissue
sections stained with anti- human HLA-DR (upper 2 panels) and HIV-1p24 (bottom panels). f Total human CD45+ leukocytes, CD3+ and subpopulations
of CD4+ and CD8 T+ cells from blood of control (n= 15) and HIV-1 infected (n= 40) mice. g Plasma viral load was consist among the animals in both
acute (14 days) and chronic (16 weeks) infectious paradigms, n= 54. One-way ANOVA and Bonferroni’s post-hoc tests for multiple comparisons and two-
tailed Student’s t-test were used for statistical analyses in a and f. *P < 0.05, ***P < 0.001. Source data are provided as a source data file
Table 1 Cell and animal PK data sets for the LASER ART nanoformulations
NMDTG NM3TC NMABC NRPV
Macrophage Uptake, Retention and Antiretroviral
Activity
Maximal prodrug uptake (μg/106 cells) 74.3 10.4 11.3 31.6
Prodrug retention (μg/106 cells) 10.0 ND 5.0 17.9
Drug Concentration tested (μM) 100 100 100 100
Multiplicity of infections (MOI) 0.01 0.01 0.01 0.01
Percent of HIV-1 inhibition (%) ND 99 99 99
Pharmacokinetics λz (1/day) 0.0506 0.6584 ND 0.1274
t1/2 (day) 13.77 1.05 ND 5.44
AUC last (daya ng/ml) 38995.2 1187.0 315.4 13694.9
AUC 0-∞ (daya ng/ml) 40727.9 1187.4 1513.8 13706.7
AUC % Extrapolation 4.34 0.03 79.17 0.086
Vb/F (L/kg) 22.1 64.0 ND 25.8
CL/F (L/day/kg) 1.1 42.1 ND 3.3
MRT 0-∞ 14.53 2.27 5.53 3.77
Tabular representation of in vitro activity of each of the four nanoformulated long-acting antiretroviral drugs (NMDTG, NM3TC, NMABC, and NRPV). The pharmacokinetic (PK) profile of each of the
nanoformulated drugs are illustrated with accompanying doses for mouse testing. The various parameters of PK measurement include terminal rate constant (slowest rate constant), (λz), terminal half-
life (t1/2), area under the concentration-time curve (AUC), apparent volume of distribution after IM administration (Vb/F), apparent total plasma or serum clearance of drug after injection (CL/F), mean
resident time (of the unchanged drug in the systemic circulation) (MRT). Source data are provided as a source data file.
HIV-1ADA challenge 10 days after loading
ND could not be determined; no significant decline in drug levels from day 1 to day 14 after treatment
aDoses: Single IM injection into mice; NMDTG, NMABC and NRPV= 45mg/kg as DTG, ABC and RPV equivalents; NM3TC= 50mg/kg as 3TC equivalents
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15 ± 6% and < 6% in groups 2 and 1, respectively (Fig. 2b). The
CD4+ T cell profile of each animal is shown (Fig. 3) for all
treatment groups. Disease was determined by declining percen-
tages of CD4+ T cells. Results showed a robust restoration of
CD4+ T cells in the animals that received LASER ART alone or
in combination with AAV9-CRISPR-Cas9 as compared to
infected controls and AAV9-CRISPR-Cas9 alone treated animals
(Figs. 2b and 3).
Next, we evaluated the number of total human cells (CD45+ )
and T cells (CD3+ ) by flow cytometry and demonstrated
sustained human cell numbers in both control (uninfected),
infected and treated animals at and beyond four months until the
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study conclusion (Fig. 4a, b respectively). The presence of human
CD4+ cells (Fig. 4c) and HLA-DR in spleen was observed to
confirm graft stability. We also observed restoration of CD4+
T cells in spleens of dual-treated animals (Fig. 4c). This was
further confirmed by the identification of species-specific DNA
sequences in spleens of all animal groups independent of
treatments administered (Fig. 4d). Indeed, cell numbers proved
constant following all CRISPR-Cas9 and LASER ART
interventions.
HIV-1 elimination in LASER ART and CRISPR-Cas9-treated
mice. Next, we determined viral DNA and RNA levels in tissues
(Fig. 5) using ultrasensitive semi-nested real-time qPCR with
primers and probes designed for detection of HIV-1 gag. DNA
analysis revealed that combination treatment (n= 7) was more
effective than either LASER ART (n= 10) or CRISPR-Cas9 alone
(n= 6) in DNA copy reductions. The spleen, bone marrow (BM),
gut, brain, liver, kidney, and lung of mice M4346 and
M4349 showed no rebound. Results from targeted qPCR for DNA
sequence detection excluded the presence of DNA corresponding
to pol and env genes in the two, dual-treated and virus eradicated
animals (Fig. 5a–c). Similarly, results from the RNA detection
assay corroborated these results and showed that combination of
LASER ART and CRISPR-Cas9 reduced HIV-1 RNA in select
animals with complete absence of viral RNA in M4346 and
M4349 (Fig. 5d). The presence of HIV-1 RNA was also examined
by RNAscope using 5 μm thick spleen sections from infected
animals and antisense probe V-HIV-1 Clade-B designed for
targeting base pairs 854–8291 of HIV-1NL4–3 (Fig. 5e). Viral DNA
and RNA were not detected in plasma or tissues from both mice.
Cells and tissues obtained from mouse M4346 contained no viral
nucleic acid (Fig. 5e). Further evidence supporting the absence of
HIV-1 genomes in animals M4346 and M4349 was provided by
digital droplet PCR (ddPCR) (supplementary fig. 2). Verifying
prior qPCR results, no viral DNA/RNA (assay’s detection sensi-
tivity of < 2 viral copies) was detected in spleen, bone marrow,
and gut of mice M4346 and M4349. The data, taken together, all
support the findings of complete HIV-1 elimination. In further
cross validation tests, viral rescue assays were performed by co-
culturing bone marrow cells and splenocytes of representative
animals with phytohemaglutinin/interleukin-2 (PHA/IL-2)-
stimulated peripheral blood mononuclear cells (PBMCs). These
tests were performed for an additional two weeks. Representative
data from these experiments showed that while HIV-1 was res-
cued from 100% of samples with detectable viral DNA and RNA,
no evidence for virus recovery was observed in the samples from
the two animals (M4346 and M4349) where HIV-1 DNA and
RNA were eliminated despite the presence of high numbers of
human cells (supplementary fig. 3).
On and Off target CRISPR-Cas9 effects. We next evaluated on
and off target CRISPR-Cas9 effects in infected and treated ani-
mals. In these experiments, gel electrophoresis was performed in
PCR-amplified DNA fragments from infected and treated animals
using pairs of primers designed to detect cleavage (Fig. 6). As
expected, excision of viral DNA fragments was readily observed
from spleen, gut, and kidney samples of animals treated with
LASER ART and CRISPR-Cas9 (Fig. 6b). Excision of the pre-
dicted fragment in lung, liver, and brain amongst other tissues
was also observed (supplementary fig. 4). The excision type dif-
fered in the various tissues amongst animals. The integrity and
precision of the HIV-1 DNA excision by CRISPR-Cas9 were
verified by sequencing (Fig. 6c, and supplementary figs. 5–7). In
mice that received CRISPR-Cas9 without LASER ART, frag-
mental deletion was detected. Several other DNA fragments in
tissues from animals that received LASER ART alone were
amplified, but after sequencing were found unrelated to HIV or
CRISPR-Cas9 editing. This observation likely represented repli-
cation defective HIV-1 (highlighted by double asterisks, Fig. 6b).
The efficiency of the proviral DNA excision by CRISPR-Cas9 in
the spleens of two infected humanized mice from the CRISPR-
Cas9 and LASER ART group (animals where no rebound was
observed) was determined by ddPCR. Excision efficiency was
estimated to be 80% in both 5′-LTR-Gag and Gag to 3’-LTR in
mouse M4349. Transduction efficiency was determined by
ddPCR and ranged from 0.12–1.03 AAV vector copies/cell
(Fig. 6d–f). Amplification of the DNA fragments corresponding
to the control housekeeping actin gene in tissues and expression
of gRNAs and Cas9 are shown in supplementary fig 8.
Clustering analysis revealed similar excision patterns with high
efficiency across the tissues in animals that received dual
treatments compared to those that received CRISPR-Cas9 alone
(supplementary fig. 9). However, results from sequencing of
several selected sites with high scores of specificities and/or their
locations in the exons ruled out off-target effects (supplementary
figs. 10 and 11, and supplementary table 3). Further, results from
whole genome deep sequencing of DNA from spleens of four
treated animals, including two animals that showed no rebound
after dual treatment and one from each of the two single
treatment groups was performed and then confirmed by
bioinformatics analyses. No detectable off target effects on more
than one hundred predicted sites that were seen can be attributed
to CRISPR. This was done by identifying somatic genomic
alterations including structural variants (SVs), single nucleotide
polymorphisms (SNPs), copy number variations (CNVs) and
Fig. 2 Viral load and CD4+ T cells in HIV-1 infected and treated humanized mice. Mice were infected with 104 TCID50 of HIV-1NL4–3 followed by
treatments with LASER ART, CRISPR-Cas9 or both. a The study scheme shows the times of infection and treatments. After confirmation of viral infection,
29 infected humanized mice were subdivided into four groups. The first group (n= 6, red) were left untreated (control), the second group (n= 6, black)
received a single intravenous (IV) dose of AAV9-CRISPR-Cas9 (1012 units), nine weeks after viral infection, the third group (n= 10, blue) were
administered LASER ART (NMDTG and NRPV at 45mg/kg and NMABC and NM3TC at 40mg/mg) by intramuscular (IM) injection two weeks after viral
infection, the fourth (n= 7, green) were given LASER ART (as in group 3) and three weeks after the last LASER ART treatment, a single IV dose of AAV9-
CRISPR-Cas9 was administered as in group 2. LASER ART treatment was ceased and after an additional five weeks, antiretroviral drug levels were assessed
and were at or below the limit of quantitation < 1 ng/ml (Table 1). b Flow cytometry for human CD4+ T cells are shown with increased numbers of CD4
counts in the LASER ART and dual LASER ART and CRISPR-Cas9 groups. c Evaluation of plasma viral load indicated that after administration of AAV9-
CRISPR-Cas9, 2 of 7 mice showed no evidence for viral rebound at 14 weeks. d Plasma viral load of individual animals for different treatment groups of
humanized mice were assayed at 2, 7, 9, and 14 weeks of HIV-1 infection for HIV-1 RNA. Viral RNA levels were determined by the COBAS Ampliprep-
Taqman-48 V2.0 assay with a sensitivity of 200 copies/ml once adjusted to the plasma dilution factor. Viral RNA rebound was observed at the study end
in all 10 LASER ART treated animals. This corresponded to eight weeks after therapy interruption. Rebound was also observed at the study end in 5 of 7
dual-treated animals. Virus was not observed in two dual-treated animals (M4346 and M4349) and are highlighted in the red boxes. Source data are
provided as a source data file
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small insertion and deletion (InDel) mutations under different
treatments and comparing these with all potential off-targets
(supplementary Tables 1–5 and figs. 10–13).
Validation for LASER ART and CRISPR-Cas9 HIV-1 ther-
apeutic elimination. To validate eradication of HIV-1 infection,
we performed replicate experiments in a separate set of HSC-
reconstituted NSG mice infected with a second macrophage
tropic viral strain (HIV-1ADA) (Fig. 7a). Animals were infected
with 104 TCID50 of HIV-1ADA for two-weeks, at which time
depletion of CD4+ T cells was observed and viral RNA copies in
plasma were recorded at a median level of 8.4 × 104 copies/ml
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(Fig. 7b–c). Semi-nested real-time qPCR of HIV-1 nucleic acid
confirmed tissue viral infection from three representative animals.
Infected animals were divided into three groups, a no treatment
infected group (n= 4); those that received LASER ART (combi-
nations of DTG, RPV, 3TC, and ABC) with (n= 6) or without
CRISPR-Cas9 (n= 7). Animals were observed for ten weeks after
cessation of LASER ART for viral rebound. Continuous viral
replication was readily observed in untreated animals and those
treated with only LASER ART. Notably, three of six LASER ART
and CRISPR-Cas9-dual-treated animals had no demonstrable
viral rebound (Fig. 7c). In these mice, protection of CD4+ T cell
counts (71.3 ± 3.5%) was observed compared to infected controls
(48.3 ± 4.5%) (Fig. 7b). The CD4+ T cell and viral load profiles
for each of the individual animals are shown (supplementary
figs. 14–15). As in the first experiment, detection of human DNA
sequences in spleen confirmed uniform presence of human cells
in lymphoid tissues of all humanized mice regardless of treat-
ment. Moreover, no evidence of viral gene expression was found
in another two animals (M3319 and M3336) employing qPCR
tests for DNA sequence detection (Fig. 7d). HIV-1 genome
amplification was also absent in these two mice and were con-
firmed by the ddPCR (Fig. 8a) and RNAscope tests (supple-
mentary fig. 16). One animal out of three that had no
demonstrable rebound in plasma showed detectable HIV-1 DNA
in tissues (split red-black structure, Fig. 7d), confirming the
important role that tissue reservoirs play during HIV-1 infection.
Viral DNA by PCR, gel electrophoresis, and Sanger sequencing
verified the ability of CRISPR-Cas9 to excise the target DNA
fragment positioned between the LTR and GagD (Fig. 8b and
supplementary fig. 17).
Finally, splenocytes and bone marrow cells were isolated from
HIV-1 infected mice with or without prior LASER ART and/or
CRISPR-Cas9 treatments at the study end. These cells were
used in adoptive transfer studies performed in uninfected drug
naive humanized mice to examine the potential rebound from
latent reservoirs not detected by standard ddPCR and nested
PCR. In addition, as positive controls, two animals from the HIV-
1 infected group, one from the LASER ART alone treatment
group and five animals from the dual treatment group were used
as controls for adoptive transfers (Fig. 8c and supplementary
fig. 18). Recipient mice were sacrificed after 30 days and analyzed
for plasma viral RNA. Virus was not detected in plasma
from animals that received splenocytes or bone marrow cells
isolated from sequentially LASER ART CRISPR Cas9-treated
animals (M3319 and M3336). In contrast, virus was readily
identified in all virus infected or virus infected and LASER ART
treated animals. One animal each from the HIV-1- and dual-
treated bone marrow injected group died prior to the assay
performance and as such these data were not included. In
conclusion, the in vivo viral outgrowth assays performed from
virus eliminated dual-treated mice to new uninfected recipient
humanized mice failed to demonstrate viral recovery after one
month following adoptive transfers (Fig. 8c). Also, no histo-
pathological evidence for cytotoxicities were detected in any of
the animals by conventional microscopic test evaluations of liver
(supplementary fig. 19).
To provide an additional level of confirmation to these
observations, a third series of studies using replicate procedures
were performed. Here, we confirmed the ability of LASER ART
and CRISPR-Cas9 to eliminate viral rebound in a new cohort of
CD34+HSC-reconstituted animals infected with HIV-1ADA. The
outcome of the virological assays showed no evidence of the
presence of replication competent virus in four out of ten animals
tested after removal of LASER ART in the dual therapy group
(supplementary Table 6). All HIV-1 animals that received no or
single treatments showed viral rebound after treatment was
stopped. Notably, in all three experiments and in all treatment
groups, no demonstrable changes in the animals’ well-being or
histopathology were observed.
Altogether, the results from three independent sets of studies
revealed that a third or more of the animals that received
sequential LASER ART and CRISPR-Cas9 therapy became virus
free (supplementary Table 6). Most likely, successful outcomes for
virus elimination in these animals reflect a combination of factors
that include viral set points, extent of a previously established
tissue viral reservoir, efficient intracellular and tissue delivery of
LASER ART, transduction efficiency and excision therapy at sites
of viral growth. Future work will begin to dissect each and all of
these factors pointing to viral elimination pathways.
LASER ART was administered then removed with consequent
CRISPR-Cas9 excision. Plasma drug levels were monitored
until they reached levels that were at or below the limit
of detection. In these three independent experiments, one with
HIV-1NL4–3 and the other two with HIV-1ADA infection of
humanized mice, single treatments with LASER ART or AAV9-
CRISPR-Cas9 resulted in viral rebound in 100% of treated
infected animals. In dual LASER ART and AAV9-CRISPR-Cas9-
treated mice, virus was eliminated from cell and tissue reservoirs
in up to a third of infected animals as illustrated (Fig. 9).
Discussion
While ART has transformed HIV-1 infection into a chronic
treatable disease, virus persists in tissues that include the gut,
lymph nodes, brain, spleen amongst other sites. The inability of
ART to eliminate virus in these tissue sanctuaries remains the
major obstacle towards a disease cure. Such a limitation is linked,
in large measure, to continuous long-term infections in CD4+
memory T cells and less frequently in mononuclear phagocytes
despite both directed host antiviral immunity and ART effec-
tiveness. Thus, one may predict that, any or all steps towards HIV
elimination must include precise targeted ART delivery, main-
tenance of vigorous immune control, effective blockade of viral
growth and immune-based elimination of pools of infected cells
or genome integrated proviral DNA. Even under these condi-
tions, the presence of replication competent virus that allows low-
levels of viral production and viral latency underscores employ-
ment of strategies that eliminate virus that is integrated but latent.
Because of notable graft versus host disease in several humanized
Fig. 3 Human CD4+ T cells in HIV-1 infected and treated humanized mice. a–d Peripheral blood of humanized mice was assayed before and 2, 7, 9, and
14 weeks after HIV-1NL4-3 infection and the presence of human CD4+ cells from CD3+ gated populations were examined. a Percentage of human CD4+
T cells followed a decreased pattern in all mice (n= 6, red) in the HIV-1 infected group. b Percentage of human CD4+ T cells were decreased in all mice
(n= 6, black) in the HIV-1 infected and AAV9-CRISPR-Cas9 group. c CD4+ T cell profile of HIV-1 infected and LASER ART animals (n= 10, blue) showed
a decline in CD4+ T cell numbers two weeks after viral infection. LASER ART was eliminated eight weeks after treatment. d CD4+ T cells of HIV-1
infected and LASER ART and AAV9-CRISPR-Cas9-treated animals (n= 7, green). Decreased CD4+ T cell numbers were seen as early as two weeks after
infection. At this time, LASER ART was administered for four weeks followed by AAV9-CRISPR-Cas9 given at week 9. The mice were then followed for an
additional five weeks. Restoration of CD4+ T cells was observed in both LASER ART and LASER ART and AAV9-CRISPR-Cas9 treatment groups. Source
data are provided as a source data file
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animal models, examinations for time periods measured in
months are limited. In order to overcome the challenge of sus-
tained human grafts in mice, we adopted NSG-humanized mice
transplanted at birth with HSC. Both human myeloid and lym-
phoid lineages were successfully reconstituted in these mice and
support the evaluations of HIV-1 persistence, treatment, and
immune functions17,30–38. The sustained human grafts as con-
firmed by flow cytometry were viable and functional for more
than 6 months, which provided a platform that allowed treatment
interventions for prolonged time periods and a clear ability
during ART to best establish a continuous latent HIV-1 reservoir
in peripheral tissues and the brain and the noted immunological
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responses to the viral infection12,17,29,36,37,39. These previously
published data support the successful use of humanized mice in
studies of HIV/AIDS pathogenesis, therapeutics40–42, and treat-
ment12–14,16,18,29,43,44. These studies, taken together, clearly
provide a rationale for the scientific approaches taken in the
current report12,13,29,43,45–47.
Therefore, our approaches towards evaluating viral cures have
included the demonstrated ability of the drugs to reach sites of
latent infection and to do so at significant levels18,37,39,43,44.
Notably, the use of molecular tools can permanently eliminate the
viral genome and preclude reactivation20,21,24,48. Thus, we sug-
gest that the current successful outcome in achieving this goal in
more than 30% of the infected experimental animals reflects the
combinatorial use of a suitable animal model, control of viral set
points, reach to the viral reservoirs, delivery and intracellular drug
penetration of potent LASER ART, and the widespread employ-
ment of CRISPR-Cas9 gene editing. The latter enabled high
efficiency excision of large fragments of the viral genome from
anatomically privileged tissues. Results support the idea that
maximal viral restriction must be first established prior to exci-
sion to achieve optimal viral editing by CRISPR-Cas9.
Current HIV-1 treatment patterns are defined by daily dosing
of a combination of either two nucleoside reverse transcriptase
inhibitors (NRTIs) and one integrase strand transfer inhibitor
(INSTI), or two NRTIs and one nonnucleoside reverse tran-
scriptase inhibitor. Rebound that follows affects both the number
and function of CD4+ T cells leading to virus-associated co-
morbid conditions. LASER ART was developed in an attempt to
eliminate these limitations and was shown effective in establish-
ing drug depots in macrophages with sustained antiretroviral
activities and reductions in HIV-1 proviral load beyond ART
alone15,38,47,49–55. The success in these prior studies led to the use
of LASER ART in the current report in order to maximize ART
ingress to cell and tissue sites of viral replication enabling the
drugs to reach these sites at high concentrations for sustained
time periods. The maintenance of slow drug release for times
measured in weeks or longer provided optimal settings for viral
excision17,39,47. ART particles coated with poloxamers enabled
lipophilic hydrophobic prodrug crystals to readily cross cell and
tissue barriers, aiding precision drug release to viral sanctuary
sites12–14,37,39,46. These claims are reinforced by our prior studies
demonstrating up to a 10-fold increase in viral restriction at two
independent multiplicities of infection in CD4+ T cell lines with
LASER ART when compared to conventional native drugs12,13.
The advantages of LASER ART over native ART include rapid
entry across cell membranes of both CD4+ T cells and macro-
phages (due to drug lipophilicity); accelerated antiretroviral drug
entry into viral reservoir sites (including the brain, gut, lymph
nodes, liver, bone marrow and spleen); increased intracellular
drug delivery; and stable plasma concentrations observed over
weeks to months. The ART were selected in order to produce
sustained plasma concentrations 4X the protein-adjusted 90%
inhibitory concentration. Notably, a single parenteral dose of
NMDTG at 45 mg DTG equivalents/kg to mice provided plasma
DTG concentration of 88 ng/ml at 56 days32. Liver, spleen and
lymph node DTG concentrations were 8.0, 31.2 and 17.6 ng/g,
respectively at 56 days following single treatment. At 14 days after
NMABC and NM3TC given at 50 mg ABC or 3TC equivalents/kg
to mice, ABC and 3TC plasma concentrations were 21 and < 7 ng/
ml, respectively12–14. In summary, there was little to no residual
ART in plasma or tissue at the time of animal sacrifice reflecting
the robust viral rebound found in all infected mice treated with
LASER ART alone. Further, significant efforts were made by us to
demonstrate that one month after LASER ART was discontinued,
viral rebound was detectable. All of this highlights the rationale
for use of LASER ART over native ART. Most importantly, our
research12–14 demonstrated that ART levels in plasma were
undetectable during the period of measured viral rebound.
For elimination of proviral DNA, we chose the CRISPR-Cas9
gene editing platform and created a multiplex of gRNAs that
caused cleavage of the viral genome at the highly conserved
regions within the LTRs and the Gag gene. This strategy allowed
for the removal of the large intervening DNA fragments across
the viral genome and mitigated any chance for the emergence of
virus escape mutants20,23. In support of this notion, results from
cell culture and animal adoptive infection studies showed the
absence of replication competent HIV-1 in the spleen and bone
marrow of animals with no rebound that could be attributed to
virus escape. Our choice for the use of AAV9 comes from earlier
studies demonstrating the broad range tissue distribution of
CRISPR-Cas9 in a mouse model20. Accordingly, the results in our
current study verified the bioavailability of our gene editing
molecule in various organs of the NSG humanized mice. No off-
target effects were detected in in vivo deep sequencing and
bioinformatics analysis that may be caused by the CRISPR-Cas9
editing strategy. Nevertheless, as expected naturally occurring
cellular DNA variation was found in both untreated cells as well
as in CRISPR-Cas9-treated cells. Examination of several potential
target cellular genes performed on clonal cells expressing
CRISPR-Cas9 by gene amplification and direct sequencing
showed no mutations that may be caused by the presence of
CRISPR-Cas9 in the cells.
Results from ddPCR showed 60% to 80% efficiency of viral
DNA excision by CRISPR-Cas9. Of note, this approach quantified
dual cleavage events that removed the DNA fragment spanning
5’LTR to 3’LTR, 5’LTR to gag, and gag to 3’LTR of the proviral
genome. However, the occurrence of single site editing events that
would permanently interrupt the viral DNA and potentially
inactivate viral replication by introducing small InDel mutations
at the cleavage sites are not included in this estimate19. Therefore,
viral activation and rebound may not be observed under the
conditions whereby excision efficiency is less than 100%. In
Fig. 4 Human leukocytes in blood and spleens of humanized mice. a, b Peripheral blood of HSC reconstituted mice was assayed before and after 2, 7, 9, and
14 weeks of HIV-1NL4–3 infection for human CD45+ (A) and CD3+ (B) cells. The experiments were performed to assess levels of humanization and
percentage of total CD3+ T cells throughout the study. These included uninfected (n= 3, green), HIV-1NL4–3 infected (n= 6, red), HIV-1 and AAV9-
CRISPR-Cas9-treated (n= 6, black), HIV-1 and LASER ART (n= 10, blue), and HIV-1 and LASER ART and AAV9-CRISPR-Cas9 (n= 7, blue/black) treated
mice. All are shown from data generated from the experiments outlined in Fig. 3. In the HIV-1 infected mice group, the numbers of CD45+ and CD3+
human cells in blood of mice were comparable to the treatment groups. We did not observe any differences amongst time points when compared to
control uninfected and untreated animals. c Immunohistochemistry was performed in spleens of HIV-1 infected mice to confirm T cell reconstitution. Here,
the spleens of infected animals treated with LASER ART or both LASER ART and CRISPR-Cas9 were examined for the presence and numbers of CD4+
T cells. Significant reductions in CD4+ T cells (brown stained cells) were seen readily in the HIV-1-infected control mice. These cells were protected in
HIV-1 infected animals treated with LASER ART with or without CRISPR-Cas9. Scale bar, 10 μm. d Verification of the presence of human cells in the spleens
of humanized mice. PCR analysis of genomic DNA isolated from the spleens of humanized mice using primer sets specific to human and mouse beta-
globin. Source data are provided as a source data file
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recent studies, we demonstrated that inclusion of quadruplex of
gRNAs for targeting Gag, Pol and two separate sites within the
LTRs may yield slightly higher efficiency of viral DNA excision24.
It is important to note that in those studies we employed a dif-
ferent mouse model, distinct AAV delivery system, and more
importantly, different timelines for HIV-1 infection and viral
DNA harvesting for conventional semi-quantitative PCR assays.
In recent studies, we combined bioimaging, antiretroviral PK and
sensitive tissue biodistribution studies to facilitate ART delivery
into cell and tissue viral reservoirs in both humanized mice and
non-human primates. These combined diagnostic and ther-
apeutic modalities, coined theranostics, are being developed to
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facilitate effective HIV-1 elimination strategies in an infected
human host56.
In conclusion, we employed a broad range of highly sensitive
tests to evaluate HIV-1 elimination by LASER ART and AAV9-
delivered CRISPR-Cas9 treatments. These included viral gene
amplification, flow cytometry, adoptive viral transfers, on target
and off target assays, and measures of viral rebound to demon-
strate that combination therapies can safely lead to the elimina-
tion of HIV-1 infection. Results demonstrated that eradication of
replication-competent HIV-1 present in infectious cell and tissue
sites of infected animals can be achieved. Although reappearance
of viremia in humans can be delayed6, rebound occurs on average
2 to 4 weeks after ART interruption6,57,58 and 5 to 11 days in
humanized mice59. Despite the vigorous treatments offered, there
was no evidence of outward untoward effects of any therapies
(supplementary fig. 19)12 including the persistence of human
adult lymphocytes in mouse plasma and tissue (Fig. 4). As such,
these proof-of-concept results offer readily defined and realistic
pathways toward strategies for HIV-1 elimination. Future studies
are designed to improve delivery of agents to viral reservoirs and
specifically eliminate residual latent viral infections. This is a first
important step towards a longer journey for viral eradication.
Methods
Cell culture reagents. 4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid
(HEPES) buffer and ciprofloxacin were purchased from Sigma-Aldrich, St. Louis,
MO. Diethyl ether, endotoxin-free water, gentamicin, acetonitrile (ACN), metha-
nol, KH2PO4, bovine serum albumin (BSA), Triton X-100, LC-MS-grade water,
and TRIzol reagent were purchased from Fisher Scientific, San Diego, CA. The
TZM-bl reporter cell line (AIDS Reagent Program, Division of AIDS, NIAID, NIH,
Bethesda, MD) and HEK-293T cells (the American Type Culture Collection
(ATCC), Manassas, VA) were cultured in high glucose DMEM supplemented with
10% FBS and gentamicin (10 µg/ml). Jurkat (Clone E6–1, TIB-152™) cells were
purchased from ATCC and cultured in Roswell Park Memorial Institute (RPMI)
medium containing 10% FBS and gentamicin (10 µg/ml) (Sigma-Aldrich, St. Louis,
MO). PBMCs were isolated from leukopaks by gradient centrifugation on Ficoll-
Paque for 30 minutes at 600 g. PBMCs collected from the buffy coat were stimu-
lated with PHA (5 µg/ml) for 24 h in RPMI with 10% FBS and gentamicin (10 µg/
ml) supplemented with human recombinant interleukin-2 (rIL-2) at a concentra-
tion of 30 ng/ml ((STEMCELL Technologies, Seattle, WA). Fresh media was
exchanged every 2–3 days.
Cell culture HIV-1 infection. HEK-293T cells were transfected using CaPO4
precipitation method in the presence of chloroquine (50 µM) with 30 µg of pNL4–3-
EGFP-P2A-Nef plasmid22 /2.5 × 106 cells/100 mm dish. Next day, media were
replaced; and 24 and 48 h later supernatants were collected, clarified at 1400 g for
10 minutes, filtered through 0.45 µm filter, and concentrated by ultracentrifugation
for 2 h with 20% sucrose cushion. Viral pellets were resuspended in Hank’s Basic
Salt Solution (HBSS) by gentle agitation overnight, aliquoted, and tittered in Jurkat
cells by FACS for GFP expression. Jurkat cells were infected by spinoculation for
1.5 h, 32 °C in 500 µl inoculum containing 8 µg/ml polybrene then resuspended and
left for 4 h then 500 µl of growth medium was added. Next day, cells were washed 3
times with phosphate-buffered saline (PBS) and re-suspended in growth medium.
Design of gRNA, construction of CRISPR-Cas9 expression plasmid and the
AAV9 vector. Bioinformatics design and cloning of LTR1 and GagD gRNAs into
AAV-CMV-saCas9 vector was previously described19,23. Briefly, the Broad
Institute gRNA designer tool (https://www.broadinstitute.org/rnai/public/
analysis-tools/sgrna-design) was used to screen HIV-1NL4–3 or ADA sequences for
possible gRNA protospacer regions followed by saCas9 specific PAM: NGGRR
(N). A pair of gRNAs showing the best predicted on-target (in HIV-1 genome)
and the lowest off-target (in human genome) activities was selected: one tar-
geting the HIV-1 LTR promoter region and the other targeting gag gene. The
sequences of respective LTR1 and GagD gRNAs plus PAM were further cross
referenced with Los Alamos HIV sequence database confirming high levels of
conservation (>90%) across the HIV-1 sequences. Next, pair of oligonucleotides
for each target site with 5′-CACC and 3′-AAAC Bsa1 overhangs was obtained
from Integrated DNA Technologies (IDT, Coralville, Iowa, Table S1), annealed,
phosphorylated, and ligated into BsaI digested, dephosphorylated pX601-AAV-
CMV:NLS-saCas9-NLS-3xHA-bGHpA;U6::BsaI-sgRNA (a gift from Feng Zhang
via Addgene) (61591; Addgene). For multiplex gRNA cloning, the U6-LTR1-
gRNAscaffold cassette from pX601-CMV-saCas9-LTR1 was amplified using
T795/T796 primers (Table S1) and cloned using In-Fusion HD Cloning Kit
(Clontech, Mountain View, CA) into EcoRI and KpnI linearized pX601-CMV-
saCas9-GagD plasmid resulting in pX601-CMV-saCas9-LTR1-GagD AAV
delivery vector. Finally, sequence verified plasmid was sent for packaging into
AAV-9 serotype (Vigene Biosciences Inc., Milton Park Abingdon, UK). AAV9
was chosen as the vector for CRISPR-Cas9 delivery for its robust transduction
efficiencies in multiple tissues including the central nervous system as significant
putative reservoirs for HIV-1. The notion was to permit efficient AAV entry into
all putative HIV-1 target tissues including the brain.
HIV-1 infection of CD34+ humanized mice. NSG (NOD.Cg-Prkdcscid
Il2rgtm1Wjl/SzJ) mice were obtained from the Jackson Laboratories, Bar Harbor,
ME and bred under specific pathogen-free conditions at the University of Nebraska
Medical Center (UNMC) in accordance with the ethical guidelines set forth by the
National Institutes of Health for care of laboratory animals. CD34+HSC were
enriched from human cord blood or fetal liver cells using immune-magnetic beads
(CD34+ selection kit; Miltenyi Biotec Inc., Auburn, CA, USA). CD34+ cell purity
was >90% by flow cytometry. Cells were transplanted into newborn mice irradiated
at 1 Gy using a RS‐2000 × ‐Ray Irradiator (Rad Source Technologies, Buford, GA).
Cells were transplanted by intrahepatic (i.h.) injection of 50,000 cells/mouse in 20
μl phosphate-buffered saline (PBS) with a 30-gauge needle. The experiments shown
in Fig. 2–6 were from human fetal liver cells were isolated from a single donor. In
the study described in Figs. 7 and 8, cord blood-derived HSC were obtained from
two donors. Mice from a single donor were used for all dual treatment mice.
Humanization of the animals was affirmed by flow cytometry31,60 for the presence
of human CD45 and CD3 positive blood immune cells, as shown in Fig. 4. At
18 weeks of age, 25 NSG-hu mice were infected intraperitoneally (i.p.) with HIV-
1NL4–332,36 at 104 tissue culture infective dose50 (TCID50)/ml and sacrificed at days
1, 3, 7, and 14; n= 5 at each time point. Five control-uninfected animals were
included in all test evaluations. Levels of viral RNA copies/ml were analyzed with
the automated COBAS Ampliprep System V2.0/Taqman-48 system (Roche
Molecular Diagnostics, Basel, Switzerland)30,31. For this assay, 100 μl of mouse
serum was diluted to 1 ml with sterile filtered normal human serum. The detection
limit of the assay after dilution is 200 viral RNA copies/ml. Although the eclipse
phase for viral infection in humans remains variable61, the viral loads and CD4+ T
cell depletion levels observed in our infected humanized mice are in point of fact
reflective of the disease course in an infected human host. Indeed, only after weeks
of infection we do observe significant cell loss12,17,29,37,50. These findings can be
viewed as an affirmation of the model including CD4+ T cell timed-restorations
seen after ART as is seen in humans.
Fig. 5 Viral DNA and RNA in HIV-1 infected and treated humanized mouse tissues. a HIV-1 DNA and (d) HIV-1 RNA analyses using ultrasensitive semi-
nested real-time qPCR assays from spleen, bone marrow, gut, brain, liver, kidney, and lung from treatment groups described in Fig. 4a–c. Animal numbers
were decreased in one group due to deaths seen through the experimental observation period. The data represent each of the four groups HIV-1 infected
(n= 5), HIV-1 infected and AAV9-CRISPR-Cas9 treated (n= 6), HIV-1 infected and LASER ART treated (n= 4) and HIV-1 infected LASER ART and AAV9-
CRISPR-Cas9-treated mice (n= 7). The data are expressed as total HIV-1 DNA (a) or HIV-1 RNA (d) copies/106 human CD45+ cells. Two animals,
M4346 and M4349 [shown by the red squares below the dashed lines (detection limit)], with dual treatments, showed sterilization of virus from all
tissues analyzed. b, c Quantitative PCR showed complete elimination of signals corresponding to pol (b) and env (c) DNA sequences of HIV-1 in mice
M4346 and M4349 (shown as red triangles). One-way ANOVA and Bonferroni’s post-hoc tests for multiple comparisons and two-tailed Student’s t test
were used for comparisons between two groups for statistical analyses. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. e Representative results from
RNAscope assay revealed the detection of single or clusters of brown dots corresponding to HIV-1 RNA in 5 μm-thick spleen sections of infected animals
receiving either LASER ART or CRISPR-Cas9 alone, but not both (M4346). E1, humanized mice infected with HIV-1 (controls); E2, HIV-1 infected animals
treated only with CRISPR-Cas9; E3, HIV-1 infected LASER ART treated animals demonstrating viral rebound after cessation of therapy; E4, infected animals
treated with LASER ART followed by CRISPR-Cas9. E1-E4 are representative tissue sections taken from each of the animal groups. In these assays, we used
the antisense V-HIV1-Clade-B targeting 854–8291 bp of HIV-1 as the probe. Scale bar 40μM. Source data are provided as a source data file
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Nanoformulated antiretroviral drugs. DTG, 3TC and ABC were generous gifts
from ViiV Healthcare, Research Triangle Park, NC. RPV was purchased from
Hangzhou Bingo Chemical Co., Ltd, Hangzhou, China. Antiretroviral prodrugs
and their polymer encasements were performed as previously described12–14.
Myristoylated modifications for DTG, 3TC, and ABC were made (referred to as
MDTG, M3TC, and MABC) to enhance the incorporation into poloxamer 407
(P407) nanoparticles, while RPV was encased solely by poloxamer 338 (P338) in
unmodified form using high pressure homogenization to form crystalline nano-
formulated drugs. Particle size, polydispersity index, and zeta potential were
determined by dynamic light scattering using a Malvern Nano-ZS (Malvern,
Worcestershire, UK)49. Final drug concentrations in the nanoformulation sus-
pensions and injection solutions were determined by HPLC-UV/Vis and
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UPLC-MS/MS. A 40–50 μl volume for each nanoformulation combination
(NMDTG/NRPV and NM3TC/NMABC) was administered by intramuscular (IM)
injection in opposing thigh muscles of the mice.
Antibodies. For flow cytometric analysis, we used a panel of antibodies (all from
BD Biosciences, San Jose, CA) comprised of FITC-conjugated mouse anti-human
CD45 (catalog #555482), Alexa Fluor 700-conjugated mouse anti-human CD3
(catalog #557943), APC-conjugated mouse anti-human CD4 (catalog #555349),
and BV421-conjugated mouse anti-human CD8 (catalog #562428), PE-conjugated
mouse anti-human CD14 (catalog #555398), and PE-Cy5-conjugated mouse anti-
human CD19 (catalog #555414) antibodies. For immunohistochemical staining, we
used monoclonal mouse anti-human HIV-1p24 (clone Kal-1, M0857, Dako, 1:10),
monoclonal mouse anti-human leukocyte antigen (HLA-DR; clone CR3/43, Dako,
1:100), and the polymer-based HRP-conjugated anti-mouse EnVision+ secondary
antibodies were purchased from Dako (Carpinteria, CA). Peripheral blood was
collected from the submandibular vein into ethylenediaminetetraacetic acid
(EDTA)-coated tubes or by cardiac puncture at the study end. Blood leukocytes
were tested for human pan-CD45, CD3, CD4, CD8, CD14, and CD19 markers as
six-color combinations using LSR-II FACS analyzer (BD Biosciences). Antibodies
and isotype controls were obtained from BD Pharmingen, San Diego, CA, and
staining was analyzed with a FlowJo (BD Immunocytometry Systems, Mountain
View, CA). The gating strategy is shown in supplementary fig. 20. Results were
expressed as percentages of total number of gated lymphocytes. The percentages of
CD4 and CD8 positive cells were obtained from human CD3+ gate17. We used
absolute counts of human CD45+ cells to normalize each of the human cell data
sets. Equivalent numbers of total blood cells/mouse were used at each time point.
Immunohistochemistry (IHC) examinations. Spleen, lung, liver, and lymph
nodes were perfused with PBS followed by 4% paraformaldehyde and then post-
fixed overnight and processed for paraffin embedding. Five-micron thick sections
were cut from the paraffin blocks, mounted on glass slides, and labeled with mouse
monoclonal antibodies (Dako) for HLA-DQ/DP/DR (clone CR3/43, 1:100) and
HIV-1p24 (1:10). The polymer-based HRP-conjugated anti-mouse Dako EnVision
system was used as a secondary detection reagent and developed with 3,3′-dia-
minobenzidine (DAB). All paraffin-embedded sections were counterstained with
Mayer’s hematoxylin. Deletion of primary antibodies or using mouse IgG served as
controls. Images were obtained with a Nikon DS-Fi1 camera fixed to a Nikon
Eclipse E800 (Nikon Instruments, Melville, NY) using NIS-Elements F
3.0 software.
Nucleic acid extractions and qPCR assays. In studies presented in Fig. 2–8, total
viral nucleic acids (RNA and DNA) were extracted from the spleen, bone marrow
cells, lung, gut, liver, kidney, and brain using a Qiagen Kit (Qiagen, Hilden, Ger-
many) according to the manufacturer’s instructions. Total cellular DNA obtained
from the HIV-1 infected cell line ACH2 served as a positive control and standards,
while human genomic DNA obtained from uninfected NSG-hu mice served as a
negative control. Cell-associated HIV-1 RNA and DNA were quantified by real-
time qPCR and droplet digital PCR (ddPCR) assays. Because of extremely low
numbers of latently-infected human cells in HIV-infected NSG-hu mice after long-
term ART, detection of total HIV-1 DNA, required two rounds of PCR amplifi-
cation. The first round of PCR was performed on a conventional PCR machine
(T100 Thermal Cycler, Biorad, CA) in 25 μl of PCR reaction mix containing 500 ng
of template and 50 ng each of both primers annealing to HIV-1 gag region and the
reaction conditions are as follows: 94 °C for 3 min, followed by 15 cycles of 94 °C
for 30 s, 55 °C for 30 s, and 72 °C for 1 min. The product of the first PCR was
subsequently used as a template in the second semi-nested real-time PCR ampli-
fication performed on the ABI Step One Plus real-time PCR machine (Applied
Biosystems, Foster City, CA) using TaqMan detection probe and primers30. Two μl
of the first PCR product was diluted to 50 μl with PCR master mix containing two
primers at 0.2 μM each and 0.2 µM TaqMan dual-labeled fluorescent probe. Real-
time PCR settings were as follows: 50 °C for 2 min, then 95 °C for 10 min, followed
by 40 cycles of 95 °C for 15 s, and 60 °C for 1 min. The amplicon sizes are 221 bp
for the first round of PCR and 83 bp for the second round (real-time) PCR. DNA
extracted from ACH2 cells containing one integrated copy of HIV-1 per cell was
used as standard in serial 10-fold dilutions with HIV copy numbers ranging from
101 to 105 DNA copies/reaction36,37. Integrated DNA (iDNA) provirus was
quantified using an adapted Alu-gag PCR assay as described by Agosto et al.62 with
modifications for the second round of PCR, following prior published methods63.
Briefly, samples underwent a first-round PCR amplification (95 °C for 2 min; 20
cycles of 95 °C for 15 s, 50 °C for 15 s, and 72 °C for 150 s) using 100 nM Alu and
600 nM gag reverse primers. Five μl of the first-round product were amplified in a
nested protocol using the assay for HIV-1 gag gene (second PCR primers and
probe), as described above. First-round PCR included 3 replicates using only gag
reverse primer (gag only) to serve as background un-integrated control. Integration
levels per cell were calculated by subtracting gag-only signals from the Alu-gag
quantification. Semi-nested real-time RT-PCR on HIV-1 RNA was performed as
described36,37. The eluted cellular RNA was first subjected to DNase treatment to
remove HIV-1 DNA to avoid the interference with the quantitation. For reverse
transcription assay, random hexamers were used as primers and SuperScript III
(Invitrogen, MA) to synthesize first-strand cDNA at 42 °C for 60 min. cDNA was
used for the unspliced (usRNA) assay. Two rounds of PCR were performed under
the same PCR conditions as described for total viral DNA. For the usRNA assay,
real-time PCR was run for 45 cycles and same primers and fluorescent probe as for
the total viral DNA assay were used. Human CD45 species-specific primers and
probes were obtained from Thermo-Fisher Scientific (USA) (cat. no. 433182 for
Hs0036534_g1).
For viral excision testing, frozen tissues sent to Temple University from the
University of Nebraska Medical Center were homogenized using Bullet Blender
homogenizer (Next Advance, Averill Park, NY) using bead combinations and
settings specific for every tissue according to manufacturer’s protocols. T1 buffer
from NucleoSpin Tissue kit (Macherey-Nagel, Duren, Germany) was used for
homogenization/initial lysis followed by over-night proteinase K digestion.
Extraction of genomic DNA was completed according to the manufacturer’s
protocol. For standard PCRs (supplementary Table 1), 500 ng of extracted DNA
were subjected to PCR using Fail Safe PCR kit and buffer D (Epicentre, Madison,
WI) under the following PCR conditions: 94 °C 5min, 30 cycles (94 °C 30 s, 55 °C
30 s, 72 °C 30 s), 72 °C 7min using 1st round primers followed by nested PCR
using diluted 1st round PCR reaction. Nested PCR products were subjected to
Sanger sequencing directly if only one amplicon population was detected by
agarose gel electrophoresis. For multiple amplicons detected, in order to investigate
the composition of HIV excision, each amplicon population was separated and
purified from an agarose gel electrophoresis and then cloned into TA vector
(Invitrogen, Carlsbad, CA). Plasmid DNA containing excised HIV amplicon was
purified from each bacterial colony for Sanger sequencing (Genewiz, South
Plainfield, NJ). HIV-1 DNA was quantified using TaqMan qPCR specific for HIV-1
pol and env genes and cellular beta-globin gene as a reference (supplementary
Table 1). Prior to qPCR, genomic DNA was diluted to 10 ng/µl and then 5 µl (50
ng) were taken per reaction/well. Reaction mixtures were prepared using Platinum
Taq DNA Polymerase (Invitrogen) according to a simplified procedure64. Standard
was prepared from serial dilutions of U1 cells genomic DNA since it contains two
single copies of HIV-1 provirus per diploid genome equal to beta-globin gene copy
number. qPCR conditions: 98 °C 5min, 45 cycles (98 °C 5 min, 45 cycles (98 °C 15
s, 60 °C 30 s with acquisition, 72 °C 1 min). Reactions were carried out and data
analyzed in a LightCycler96 (Roche, Basel, Switzerland). For RT-PCR, TRIzol
reagent (Ambion, Austin, TX) was used for initial RNA extraction followed by
clean up using RNeasy kit (Qiagen, Hilden, Germany) with DNAse I digestion in
the extraction column. Total 0.5ug of RNA was used for M-MLV reverse
Fig. 6 Excision of HIV-1 DNA by CRISPR-Cas9 in HIV-1 infected humanized mice. a Schematic illustration of proviral HIV-1NL4–3 DNA highlighting the
positions of gRNA LTR1 and gRNA GagD target sites, their nucleotide compositions, and the three CRISPR-Cas9 induced break points. b Total DNA from
spleen, gut, and kidney from three groups of animals used for PCR genotyping with primers sets derived from the 5’LTR, 3’LTR, and the HIV-1 gag gene.
Predicted amplicons of 193 bp and 523 bp, which result from the excisions of DNA fragments between 5’LTR to Gag and Gag to 3’LTR, respectively, were
selected for DNA sequencing. The fragment of 396 bp represents both populations of full length LTRs, as well as the chimeric of both 5’ and 3’LTR after
excision of entire proviral genome. Single asterisks above the bands point to the specificity of fragmental HIV DNA excision by CRISPR-Cas9 as verified by
Sanger sequencing (supplementary figs. 3 and 4). The double asterisk depicts non-specific amplicons (supplementary fig. 2). The dashed boxes show the
excised HIV-1 amplicons in the two animals with no viral rebound. c Representative DNA sequences from each group were aligned to the reference LTR-
Gag region of the HIV-1NL4–3 sequence. The positions and nucleotide compositions of targets for gRNAs LTR1 and GagD are shown in green, PAM in red,
and insertion sequences in yellow. Arrows highlight positions of small and large deletions. d Schematic showing locations of each gRNA, the TaqMan probe
and the possible excision outcomes. e Representative ddPCR data for HIV-1, LTR, Gag, and Pol collected from one HIV-infected humanized mouse of each
group treated with LASER ART, LASER ART plus AAV9-CRISPR-Cas9 or AAV9-CRISPR-Cas9 only (Cas9) are shown. f TaqMan probe and primers specific
for saCas9, which was delivered by AAV9, were used to determine the AAV transduction efficiency and represented as AAV vector copies/cell. g Total
human cell population in samples was measured using TaqMan probe and primers specific for human beta-actin. Source data are provided as a source
data file
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Fig. 7 Viral elimination in a subset of HIV-1 infected and treated humanized mice. Dual LASER ART and CRISPR-Cas9 treatment resulted in viral elimination
in up to a third of HIV-1ADA infected animals. Validation was made by state of the art viral, immune, and excision detection systems. a The timeline of the
experiment showing the temporal administration of LASER ART and CRISPR-Cas9 treatments, and animal sacrifice. b The percentage of human CD4+
T cells and (c) viral loads measured in the HIV-1 infected (n= 4, red). Dual treated animals (n= 6, green) that showed no (n= 3, green) or viral rebound
(n= 3, green to red) in plasma. d HIV-1 DNA analysis was performed using ultrasensitive semi-nested real-time qPCR assays from spleen, gut, liver, lung,
brain and bone marrow from infected (n= 4, open circles) and infected and dual-treated mice (n= 6, squares). Whole bone marrowcells isolated from
three animals (out of 6) from the dual-treated rebound group were used for adoptive transfer, Therefore, the data represent n= 3 for real-time-PCR assay
for the dual-treated animals in the bone marrow adoptive transfer studies. The data are expressed as total HIV-1 DNA copies/106 human CD45+ cells.
Two animals, M3319 and M3336 (illustrated by the red squares) were below the dashed lines for virus detection as measured by plasma VL. These animals
had no detectable viral DNA after dual treatments demonstrating viral sterilization from all analyzed tissues. A single animal (M3324), as illustrated by a
half-red-black designation, had an undetectable VL in plasma, but viral DNA was amplified in all the tissues analyzed. Source data are provided as a source
data file
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transcription (Invitrogen). For gRNA expression screening specific reverse primer
(pX601gRNA scaffold/R, supplementary table 1) was used in RT reaction followed
by standard PCR using target LTR 1 or GagD sense oligos as forward primers
(supplementary table 1) and agarose gel electrophoresis. For checking saCas9
mRNA expression oligo-dT primer mix was used in RT and cDNA was subjected
to PCR using saCas9 specific primer pairs and β-actin as a reference
(supplementary table 1). Sanger sequencing results were analyzed using Clustal
Omega (EMBL-EBI) multiple sequence alignment tool and Sequence Scanner
Software 2 (Applied Biosystems).
ddPCR for detection of HIV-1 nucleic acids. ddPCR was performed based on the
water–oil emulsion droplet technology, using the ddPCR™ Supermix for Probes
reagents in the QX200™ Droplet Digital™ PCR system (Bio-Rad Laboratories,
Hercules, CA). For quantification of HIV-1 DNA, the eluted cellular DNA was
PCR-amplified36,37,63 using Taqman sets targeting the HIV-1 LTRs, gag and pol
genes and as a reference mouse or human beta-actin (supplementary Table 1). A
total of 100–200 ng DNA from each tissue was used as template for ddPCR
amplifications with the same thermal cycling conditions used for real-time q-PCR
detection. Data acquisition and analysis were done using QX200 droplet reader and
QuantaSoft™ software provided with the instrument. The genomic DNA extracted
from a total of 50,000 cells including human and mouse cells was used as template
for each ddPCR analysis. The reduction of Gag represents a deletion between
5’LTR and Gag or 5’LTR to 3’LTR, while a reduction in Pol represents the excision
between Gag to 3’LTR or 5’LTR to 3’LTR. However, a single LTR will always
remain detectable in all three conditions. Thus, we used the ratio of Gag or Pol to
LTR to estimate the excision efficiency. For example, in mouse M4349 (Fig. 6e), the
ratios of Gag/LTR and Pol/LTR are 19.7% (15 cells with detectable gag out of 76
cells with detectable LTR) and 19.5%, respectively, in the genomic DNA extracted
from the spleen of the treated mice. Thus, the excision efficiencies of 5’LTR to Gag
and Gag to 3’LTR were estimated to be about 80% for both (100%-19.7% or100% -
19.5%). In the spleen of the same mouse, the AAV9 transduction efficiency was
calculated as high as 1.03 AAV vector copies/cell in the total population including
both human graft and mouse host cells (Fig. 6g). In another mouse M4346 (Source
Data file for Fig. 6e), we demonstrated that the excision occurred mainly in Gag to
3’LTR because the ratio of Pol/LTR is 38.4% while Gag/LTR is 89.5%. Thus, the
excision efficiency was estimated at 61.6% in 5’LTR to Gag and 10.5% in Gag to
3’LTR. Nonetheless, the presence of 2 LTRs in an uncut HIV proviral DNA was not
considered in order to simplify the estimate.
RNAscope. Viral RNA was detected as single brown dots or cluster of dots in 5 μm
thick paraffin embedded spleen and lymph node tissue sections using antisense
probe V-HIV1- Clade-B (Cat no 416111) targeting 854–8291 bp of HIV-1NL4–365.
Human peptidylprolyl Isomerase B (PPIB) was used as positive control for the
spleen tissue analyzed (images were captured at 40-x magnification). All reagents
are from Advanced Cellular Diagnostics, Newark, CA.
Viral recovery. PBMCs obtained from leukopaks from HIV-1,2 seronegative
donors were stimulated with PHA and IL-2 and co-cultured with human bone
marrow or spleen cells recovered from 3 groups of CD34+HSC- NSG mice
that included HIV- 1 infected, infected and LASER ART treated, and LASER ART
and AAV9-CRISPR-Cas9-treated mice. PBMCs were used in assays after a 3-day
treatment maintained in 10% RPMI with 30 U/ml of IL-2 then co-cultured with
human bone marrow or spleen cells at concentrations of (1:5)66–68. Cells were
harvested eight days later for HIV-1 DNA (A) and RNA (B) using semi-nested
real-time qPCR assay and supernatant fluids assayed for reverse transcriptase
activity for up to day-14. Data are expressed as total HIV-1 DNA (A) or RNA (B)
copies/106 human CD45+ cells. One of the two dual-treated animals was tested
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and confirmed viral sterilization. Viral rescue was observed in other groups of
animals tested.
Adoptive transfers. Splenocytes and bone marrow cells (8–10 × 106) were har-
vested at the time of sacrifice from NSG-hu mice that were HIV-1ADA infected with
and without LASER ART and AAV9-CRISPR-Cas9. The cells were adoptively
transferred into unmanipulated 18-week old CD34+HSC-NSG mice. Cell counts
and viability tests were determined by both trypan blue and live/dead stains on the
TC-20 automated cell counter (Bio-Rad). Cells were injected IP into mice and
monitored for an additional 4 weeks. These experiments were performed to cross
validate eradication of viral infection that could occur from latent reservoirs and
not detected by either qPCR, RNAscope, and ddPCR assays. Viral load was
measured from blood samples of the adoptively transferred mice using automated
COBAS Ampliprep System V2.0/Taqman-48 system, and immune cell profiles
(CD4 and CD8+ T cells by flow cytometry) recorded, in parallel. Residual virus
from all humanized mice tissues was examined by qPCR and ddPCR assays. Virus
was not detected in plasma or tissues from two adoptively transferred animals
(mice M3319 and M3336).
Off-target analyses. TZM-bl cells were plated in 6 well plates at 1 × 105 cells/
well and co-transfected using Lipofectamine 2000 reagent (Invitrogen) with 1 µg
of control pX601-AAV-CMV:NLS-SaCas9-NLS-3xHA-bGHpA;U6::Bsa1-sgRNA
(Addgene catalog #61591) or 1 µg of pX601-LTR1-GagD (20) plasmid together
with 0.2 µg of pKLV-U6gRNA(Bbs1)-PGKpuro2ABFP (Addgene catalog
#50946) to provide puromycin selection marker. The next day, cells were
transferred into 100-mm dishes and cultured in the presence of puromycin
(Sigma) at concentration 1 µg/ml. After two weeks, surviving clones were iso-
lated using cloning cylinders (Corning, Corning, NY, USA). Genomic DNA was
prepared from each single cell clone and LTR specific PCRs followed by gel
purification; TA cloning and Sanger sequencing were performed. The clones
showing the presence of on target CRISPR-Cas9 induced InDel mutations at
target LTR 1 site in integrated HIV-1 LTR sequence (n= 6) together with two
control clones were selected for further in vitro off target analysis. The list of
potential OFF target sites in human genome for HIV-1 target LTR 1 and GagD
was created using Benchling CRISPR design tool (https://benchling.com/, sup-
plementary table 2). A total of three potential OFF target sites were chosen (the
top scorer plus two top gene specific potential off target sites, see supplementary
table 2, highlighted in yellow) for PCR based screening in selected single cell
clones. The potential OFF target regions were PCR-amplified, cloned into TA
vector, and performed Sanger sequencing (3–6 sequences/single cell clone/single
OFF target) (supplementary table 3).
The genetic variation analyses among the three treatments were performed
through the next generation sequencing (by the Novogene NGS facility) and
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bioinformatics tools for four sample animals, one animal from the LASER ART,
one animal from CRISPR-Cas9- and two no-rebound animals from the
LASER ART/CRISPR-Cas9 groups. The main objective was to detect the
possible CRISPR-Cas9 off-target sites. Besides this, some genetic variations
such as single nucleotide polymorphisms (SNP), insertion-deletions (InDels),
structural variants (SVs), and copy number variants (CNVs) were analyzed
for those four animals; and the results are in supplementary tables 4–5. After
a thorough quality control step, the resulting paired-end short-reads
were mapped to the human reference genome (Human_G1K_V37) utilizing
Burrows-Wheeler Aligner (BWA) algorithm. For the animals M4356 (CRISPR-
Cas9), M4348 and M4349 (LASER ART+ CRISPR-Cas9), and M3539
(LASER ART), the 8 coverages were reported to be 92.01%, 91.97%, 92.01%,
and 91.92%, while the sequencing depths were 36.08, 63.11, 45.22, and 15.41,
respectively.
Excision efficiencies and hierarchal clustering. The excision efficiencies for
each animal, tissue, and HIV-1 gene segment were calculated as the ratio of the
number of the sequencing-verified PCR product to all members in each group
with denoted experimental conditions (i.e. treatments, cells and tissues shown
in Figs. 3, 4, 5, 6 and supplementary fig. 4). Defined such that the excision
efficiencies can be viewed as frequentist probabilities, i.e. the ratio of the fre-
quency of occurrence of the event of interest to the total number of experi-
mental repeats. This interpretation of excision efficiencies provides the user
with a predictive value, as they can be used to set a prior expectation on the
success rate of each treatment (LASER ART, CRISPR-Cas9, and LASER ART
plus CRISPR-Cas9) in excising the desired segments of HIV-1 gene in the
studied tissues and further to relate that to the likelihood of cure. Hierarchical
clustering was performed on the efficiency values of truncation events under
different treatments and across different animals, tissues, and HIV-1 gene
segments. Once the excision efficiencies were calculated under different com-
binations of experimental conditions, the hierarchical clustering scheme was
employed to group the efficiency values into a multilevel cluster tree represented
by a dendrogram. This hierarchical clustering heat map may offer a predictive
capability for viral elimination. Bioinformatics analysis of human genome
sequence data identified human genome sites that could serve as off targets
for gRNAs designed for editing HIV-1 DNA. The corresponding efficiency
values were listed in heat-map table to make the clusters visually detectable.
To this end, three combinations were considered: i) excision probabilities of
different HIV-1 segments in 6 different tissues of animals undergoing anti-
retroviral treatment, CRISPR-Cas9 mediated editing, and the combined treat-
ments; ii) excision probabilities of different segments in different animals
under the three treatments; and iii) probabilities of observing at least one
positive band for each specified tissue in all animals. Clusters of supplementary
figs. 10–16 also include additional conditions of cure and qPCR data to iden-
tify which animals experienced complete cure and highest viral genome
eradication.
Study Approval. All experimental protocols involving the use of laboratory ani-
mals were approved by the University of Nebraska Medical Center (UNMC)
Institutional Animal Care and Use Committee (IACUC) ensuring the ethical care
and use of laboratory animals in experimental research. Human blood cells were
isolated by leukapheresis from HIV-1/2 and hepatitis seronegative donors and were
deemed exempt from approval by the Institutional Review Board (IRB) of UNMC.
Human CD34+ hematopoietic stem cells were isolated from human fetal liver
and umbilical cord blood and are exempt from UNMC IRB approval.
Statistics. The data were analyzed using GraphPad Prism 7.0 software (La Jolla,
CA) and presented as the mean ± the standard error of the mean (SEM).
Experiments were performed using a minimum of three biologically distinct
replicates. Sample sizes were not based on power analyses as the efficiency of HIV-
1 elimination was not known nor could it be projected. For comparisons of two
groups, Student’s t test (two-tailed) was used. Tissue drug levels, HIV-1 RT activity,
HIV-1p24 antigen staining, T-cell populations, viral RNA and DNA, and viral load
were analyzed by one-way ANOVA with Bonferroni correction for multiple-
comparisons. For studies with multiple time points, two-way factorial ANOVA and
Bonferroni’s post-hoc tests for multiple comparisons were performed. Extreme
outliers beyond the 99% confidence interval of the mean and 3-fold greater than
the SEM were excluded. Significant differences were determined at P < 0.05.
Reporting Summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data Availability
The sequencing data reported in this paper are included in the Source Data file. The
source data underlying Figs. 4d, 5b, c 6b, c, e, f 7f, and 8c, and Supplementary Figs. 1, 4–
12 and 17 are provided as a Source Data file. All other relevant data supporting the key
findings of this study are available within the article and its supplementary files or from
the corresponding authors upon reasonable request.
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